Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 7/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | GRM5 | P41594 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | YEATS4 | O95619 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | THRA | P10827 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1657851 | 0.98 | HPGD (0.56) | HPGDPOLBGRM5ALDH1A1GAA | |
| SCHEMBL29666361 | 0.86 | GRM5 (0.44) | HPGDPOLBGRM5ALDH1A1RECQL | |
| SCHEMBL14925214 | 0.85 | HRH4 (0.48) | HPGDPOLBGRM5ALDH1A1RECQL | |
| SCHEMBL1657049 | 0.85 | HPGD (0.60) | HPGDPOLBALDH1A1GAAL3MBTL1 | |
| SCHEMBL31482126 | 0.85 | HPGD (0.41) | HPGDPOLBGRM5ALDH1A1RECQL | |
| SCHEMBL1659661 | 0.83 | L3MBTL3 (0.41) | HPGDPOLBGRM5RECQLHSD17B10 | |
| SCHEMBL1659779 | 0.81 | VNN1 (0.44) | HPGDPOLBGRM5ALDH1A1GAA | |
| SCHEMBL10272950 | 0.81 | HCAR2 (0.55) | HPGDPOLBGRM5ALDH1A1GAA | |
| SCHEMBL31694976 | 0.80 | HTR2C (0.41) | HPGDPOLBGRM5RECQLHSD17B10 | |
| SCHEMBL10888295 | 0.79 | GRM5 (0.53) | HPGDPOLBGRM5ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1784400-B1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | LILLY CO ELI (US) | 2015-01-14 | — | — | EP | disclosed |
| US-20130231321-A1 | 2-SUBSTITUTED-ETHYNYLTHIAZOLE DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2013-09-05 | — | — | US | disclosed |
| US-8440837-B2 | 2-substituted-ethynylthiazole derivatives and uses of same | H. LUNDBECK A/S (DK) | 2013-05-14 | — | — | US | disclosed |
| EP-2490541-A1 | 2-SUBSTITUTED-ETHYNYLTHIAZOLE DERIVATIVES AND USES OF SAME | H. Lundbeck A/S (DK) | 2012-08-29 | — | — | EP | disclosed |
| WO-2011050063-A1 | 2-SUBSTITUTED-ETHYNYLTHIAZOLE DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2011-04-28 | — | — | WO | disclosed |
| US-20110092475-A1 | 2-SUBSTITUTED-ETHYNYLTHIAZOLE DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2011-04-21 | — | — | US | disclosed |
| US-7705025-B2 | Histamine H3 receptor agents, preparation and therapeutic uses | ELI LILLY AND COMPANY (US) | 2010-04-27 | — | — | US | disclosed |
| US-20100029608-A1 | Histamine H3 Receptor Agents, Preparation and Therapeutic Uses | FINLEY DON RICHARD | 2010-02-04 | — | — | US | disclosed |
| US-20100029608-A1 | Histamine H3 Receptor Agents, Preparation and Therapeutic Uses | FINLEY DON RICHARD | 2010-02-04 | — | — | US | disclosed |
| US-20100029608-A1 | Histamine H3 Receptor Agents, Preparation and Therapeutic Uses | FINLEY DON RICHARD | 2010-02-04 | — | — | US | disclosed |
| US-20090048225-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY | 2009-02-19 | — | — | US | disclosed |
| EP-1784400-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2007-05-16 | — | — | EP | disclosed |
| WO-2006023462-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048225-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | HRH3, HRH4, HCRTR1 | HPGD 1537/4885POLB 4348/4885GRM5 133/4885 |
| US-20130231321-A1 | 2-SUBSTITUTED-ETHYNYLTHIAZOLE DERIVATIVES AND USES OF SAME | SULT1E1, SULT2A1, SULT1A1 | HPGD 1114/4885POLB 4543/4885GRM5 3131/4885 |
| US-20100029608-A1 | Histamine H3 Receptor Agents, Preparation and Therapeutic Uses | HRH3, HRH4, HCRTR1 | HPGD 1463/4885POLB 4356/4885GRM5 134/4885 |
| US-20110092475-A1 | 2-SUBSTITUTED-ETHYNYLTHIAZOLE DERIVATIVES AND USES OF SAME | SULT1E1, SULT2A1, SULT1A1 | HPGD 1114/4885POLB 4543/4885GRM5 3131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.